Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports by Giulia Milano et al.
JOURNAL OF MEDICAL
CASE REPORTS
Milano et al. Journal of Medical Case Reports 2014, 8:194
http://www.jmedicalcasereports.com/content/8/1/194CASE REPORT Open AccessUncommon serum creatine phosphokinase and
lactic dehydrogenase increase during diosmin
therapy: two case reports
Giulia Milano1, Silvia Leone1, Carmen Fucile1, Maria Laura Zuccoli1, Andrea Stimamiglio2, Antonietta Martelli1
and Francesca Mattioli1*Abstract
Introduction: Short-term administration of diosmin is usually considered safe, with only minor side effects (stomach
and abdominal pain, diarrhea, dermatological disorders, and headache) occasionally observed. Within a 4-year period, a
general practitioner noticed 17 cases of mild, diosmin-induced side effects, two of which showed particular interest.
Cases presentation: Case 1: A 55-year-old Caucasian woman presented with chronic leg venous insufficiency. She was
prescribed diosmin 450mg twice a day. After 5 days of therapy, she developed pain in the legs (myalgia), and diosmin
therapy was suspended. She made a spontaneous attempt of drug rechallenge and her leg pain reappeared. Thus, she
underwent blood analysis, which showed elevation of creatine phosphokinase levels. Creatine phosphokinase values
normalized only after prolonged discontinuation of the therapy. Case 2: A 79-year-old Caucasian man, who was
diagnosed with acute hemorrhoidal syndrome. After 21 days of continuous diosmin treatment, increased levels of serum
lactic dehydrogenase were detected. In both cases a comprehensive analysis of all possible causes for enzyme elevation
was made.
Conclusions: A feasible hypothesis to explain these rare effects could be that exaggerated adrenergic activity occurred
on microcirculation, leading to an excessive peripheral vasoconstriction and subsequent ischemic damage. An individual
predisposition is strongly suggested. A concurrence of events was probably responsible for the elevation of nonspecific
tissue necrosis markers. Physicians and patients must be aware of these rare, but possible, adverse drug reactions.
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Diosmin (3′,5,7-trihydroxy-4′-methoxyflavone-7-ramno-
glucoside) is a natural bioflavonoid isolated from various
plants or derived from the flavonoid hesperidin. Cur-
rently, it is used to relieve symptoms of venous in-
sufficiency or capillary fragility, such as chronic venous
insufficiency (CVI) and hemorrhoidal attacks. Self-
medication with diosmin is frequent, since it is an over-
the-counter (OTC) drug. Usual dosage of diosmin is
1000mg daily, in two divided doses. In the case of an
acute hemorrhoidal attack, a loading dose of 3000mg* Correspondence: francesca.mattioli@unige.it
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unless otherwise stated.per day for the first 4 days is needed, followed by
1000mg twice a day (bid) for 3 days [1].
In the case of CVI (which is characterized by structural/
functional alteration of veins, and abnormal capillary
hemodynamics), the main effects of diosmin are exerted
on the walls of capacitance vessels and capillaries; it in-
duces restoration of the normal venous tone, increasing
resistance [2] and decreasing the permeability of micro-
circulation vessels [3]. Moreover, this drug also enhances
drainage from lymphatic vessels [4-6]. Diosmin causes a
significant decrease in plasmatic endothelial adhesion
molecules and reduces neutrophil activation, thus pro-
viding protection against microcirculatory damage [7].
Pharmacokinetics and oral bioavailability of flavonoids
change in relation to the qualitative composition of the
extract or food: the two main sites of metabolism ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the sulfation and the glucuronidation of the hydroxyl
groups occurs in the liver, while flavonoids are subject
to bacterial degradation in the colon. Following oral
administration, diosmin is rapidly transformed into the
active metabolite aglycone (diosmetin), by intestinal flora.
Diosmetin is promptly absorbed by the gut mucosa, dis-
tributed, and finally extensively degraded to phenolic
acids or their glycine-conjugated derivatives, which are
eliminated with the urine. Approximately half of the dose
is eliminated in the feces as unchanged diosmin or dios-
metin [8]. In humans, diosmin pharmacokinetics based
on oral administration to healthy volunteers showed a
half-life of 31.5±8.6 hours, with maximum concentration
(417±94.1ng/mL, for an oral dose of 10mg/kg) reached
after 1 hour and followed by slow decrease after 2 hours
[9]. The prolonged presence of diosmin in the blood sug-
gests an enterohepatic circulation that is known to slow
down the elimination of drugs. The same study also re-
vealed that the distribution volume of diosmin is high
(62.1±7.9L), and this may explain the low diosmin plasma
levels, in comparison to the orally administered dose.
Short-term administration of diosmin is reasonably
safe for most patients, even if it may cause mild derma-
tological, gastrointestinal, and autonomic side effects.
The most common side effects are: pruritus, erythema,
dermatitis, stomach and epigastric pain, nausea and diar-
rhea, dizziness. The first three commonest diosmin side
effects as reported by the US Food and Drug Adminis-
tration (FDA) [10] are: dermatological disorders, cardiac
arrhythmias and hemolytic anemia.
The aim of this study is to describe and assess
diosmin-related adverse events (AEs) reported by pa-
tients to their general practitioner. To the best of our
knowledge, this is the first case report of diosmin-
induced serum creatine phosphokinase (CPK) and lactic
dehydrogenase (LDH) enzyme elevation during diosmin
therapy. The aim of this study is to describe the cases
and analyze the possible causes of these observed and un-
expected adverse drug reactions (ADRs) not described in
the Summary of Product Characteristics.
Case presentation
Seventeen diosmin-related suspected ADR reports were
collected during a period of about 4 years (from January
2008 to May 2012). Table 1 shows all patients’ features
and concomitant medications. Our database contains
data about 14 women and 3 men; all patients were
Caucasian and aged between 23 and 81. Of these, 16 pa-
tients were taking the recommended therapeutic diosmin
dose: diosmin alone 450mg bid (nine patients), and dios-
min 450mg plus hesperidin 50mg three times a day (tid;
eight patients), to treat acute hemorrhoidal attacks or
CVI. Only one patient was taking a supratherapeuticdose of diosmin (900mg tid). Most of the reported side
effects usually concern gastroenterological (stomach and
epigastric pain, nausea and diarrhea) and dermatological
(hives and itching) systems. All AEs were mild to moder-
ate, no severe or life-threatening reactions requiring dose
reduction or discontinuation of the treatment occurred.
Two cases aroused our attention because they are, to
date, unique case presentations of acute, diosmin-related
enzymes elevation (CPK and LDH).
Case 1 patient is a 55-year-old Caucasian woman with
legs edema and swelling. She had been taking amiloride
5mg + hydrochlorothiazide 50mg, once daily, for several
years to treat mild hypertension. A venous Doppler was
performed, and right ostial saphenofemoral incompe-
tence was diagnosed. Thus, the physician started dios-
min 450mg bid treatment, since clinical features of this
patient seemed not to be so alarming to require major
interventions. Five days after starting diosmin treatment,
the patient complained of worsening leg pain (diffuse
myalgias), and, for this reason, at day 7, she quitted dios-
min therapy, and her myalgias disappeared after 3 days.
At day 29 she decided, without informing the physician,
to take again diosmin at the same posology previ-
ously prescribed, but her myalgias reappeared (positive
rechallenge) and after 2 days of treatment, she definitely
gave up on diosmin therapy. Three days after, her phys-
ician prescribed her some blood tests. Her serum CPK
dosage was the only out-of-range biochemical value
(1500 IU/L; normal value 39 to 308 IU/L). Her physician
excluded all other possible causes for myalgias and CPK
elevation: she did not perform unusual heavy exercise;
myocardial infarction was excluded by electrocardiogram,
echocardiography, and cardiac enzymes measurement;
besides she was taking neither statins, nor OTC drugs or
herbal remedies. Thus, her physician diagnosed that dios-
min was responsible for this AE. Two months after dios-
min suspension, in a follow-up blood test, all evaluated
hematology and serum chemistry parameters were within
the physiological range, including serum CPK (value:
180 IU/L). The association between reported symptoms
and signs, and diosmin therapy, according to the Naranjo
scale [11], was given a score of 5 (probable).
Case 2 patient is a 79-year-old Caucasian man, who
was diagnosed with acute hemorrhoidal attack. His
symptoms were severe: rectal bleeding, mucous dis-
charge, swelling around the anal area and significant
pain, therefore the physician prescribed diosmin 450mg
two tablets tid and the use of topical nifedipine (0.3g)
plus lidocaine hydrochloride (1.5g). He has been taking
amlodipine (10mg, daily) for 2 years, since he was suffer-
ing from hypertension. After 7 days of treatment with
diosmin, hemorrhoidal symptoms gradually improved,
and he fully recovered after 10 days. Despite healing, he
kept on taking diosmin, at the same dosage, for another





Drug Posology AEs Dechallenge Rechallenge Concomitant therapy
1 F 70 55 diosmin 450mg 1 bid increased CPK,
myalgia
yes* yes amiloride, hydrochlorothiazide
2 F 85 70 diosmin 450mg +
hesperidin 50mg
1 tid hives yes
3 F 65 80 diosmin 450mg +
hesperidin 50mg
1 tid hives yes
4 F 60 41 diosmin 450mg +
hesperidin 50mg
1 tid hives yes
5 F 65 81 diosmin 450mg +
hesperidin 50mg
1 tid diffused itching yes parnaparin, prednisone, citalopram,
rabeprazole, acetylsalicylic acid,
simvastatin, amlodipine
6 F 55 23 diosmin 450mg +
hesperidin 50mg
1 tid tachycardia no* local medication (for perianal
fistulectomy)
7 F 75 36 diosmin 450mg 1 bid epigastric pain,
fainting
yes lisinopril, acetylsalicylic acid
8 F 95 65 diosmin 450mg 1 bid epigastric pain yes yes amlodipine, telmisartan
9 F 68 71 diosmin 450mg 1 bid epigastric pain yes
10 F 70 53 diosmin 450mg +
hesperidin 50mg
1 tid epigastric pain yes
11 M 70 43 diosmin 450mg +
hesperidin 50mg
1 tid diarrhea yes
12 M 65 43 diosmin 450mg 1 bid diarrhea no
13 F 73 35 diosmin 450mg 1 bid itching yes
14 F 80 69 diosmin 450mg 1 bid epigastric pain no
15 F 77 66 diosmin 450mg 1 bid asthenia, nausea no
16 M 80 79 diosmin 450mg 2 tid increased LDH yes anal topical application, amlodipine
17 F 75 53 diosmin 450mg +
hesperidin 50mg
1 tid hives yes cefixime, rabeprazole, acetylsalicylic
acid, carvedilol, amlodipine,
levothyroxine, simvastatin
AEs, adverse events; bid, twice a day; CPK, creatine phosphokinase; F, female; LDH, lactic dehydrogenase; M, male; Pt, patient; tid, three times a day; *yes, means
that the side effects resolved after the drug was stopped; *no, means that the event resolved before the drug was stopped.
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and received blood tests, as part of a routine check-up.
Increased levels of LDH (1100 IU/L; normal value: 240 to
480 IU/L) were observed. It was the only out-of-range
biochemical value. After 1 month, blood tests showed a
normalization of LDH values (265 IU/L). In this case, re-
challenge was not performed. The association between
the accidentally observed LDH elevation and diosmin
therapy, according to the Naranjo scale, was given a score
of 3 (possible).
Discussion
A comprehensive review of the literature using Medline/
PubMed database was performed and a few cases of
diosmin-related ADR reports were found. In most cases
diosmin causes minor side effects, stomach and abdom-
inal pain, diarrhea, dermatological disorders, and head-
ache [12]. Few cases of hemolytic anemia have been
reported by FDA; nevertheless, no published data areavailable [10]. In order to explain the mechanisms of the
suspected diosmin-related ADRs, we verified if the AEs
might be associated with diosmin pharmacokinetics.
Despite a comprehensive and laborious review of litera-
ture, we were not able to hypothesize any pharmacoki-
netic correlation. It is not conceivable to suppose a
longer enterohepatic recycling or alteration in the excre-
tion of diosmin. Besides, we excluded, in both cases, any
possible interactions between diosmin and concomitant
antihypertensive therapies. In the Case 1 patient, the pos-
sibility of amiloride/hydrochlorothiazide-induced imbal-
ance in electrolytes (a possible cause of myalgias and other
disorders) was excluded because biochemical tests showed
no abnormalities in the serum potassium concentration
and all the other parameters were within the physiological
range. Furthermore, positive rechallenge strengthens the
hypothesis of a diosmin-related adverse reaction.
As regards to the Case 2 patient, the conditions that
can raise LDH levels (heart failure, hypothyroidism,
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LDH is often used as a marker of tissue breakdown and
can function as a marker for hemolysis, we took into ac-
count the possibility of hemolytic transient anemia,
(already described as a possible diosmin side effect by FDA
[10]) that could have occurred as a complication of the
supratherapeutic dose of diosmin (900mg tid). Neverthe-
less the absence of anemia, elevation of indirect bilirubin
and reticulocytosis allow us to exclude this hypothesis. Fi-
nally, errors in laboratory measurements were excluded.
Kumar et al. [13] reported a case of an intraventricular
hemorrhage in a 77-year-old patient during a protracted
diosmin therapy. The authors ascribed the event to the
ability of diosmin to enhance the effects of noradrenaline
on venous tone and in inhibiting platelets aggregation. The
authors also hypothesized that prolonged use of diosmin
had probably induced a chronic reinforcement of norad-
renergic tone on choroid plexus microcirculation leading
to increased intravascular pressure.
As reported by Sher et al. [14] and, more recently,
reviewed by Middleton et al. [15], diosmetin, the active
metabolite of diosmin, behaves as an antagonist of
plasma membrane amine transporters at the molecular
level, suggesting that inhibition of amine reuptake at
peripheral sympathetic nerve terminals could lead to an
increased vascular tone. However, as reported by Boudet
and Peyrin [2], diosmin vasotonic effects could also be due
to the inhibition of venous catechol-O-methyltransferase
activity with a consequent decrease in the metabolism of
noradrenaline at the vein wall; this mechanism of action
could induce peripheral vasoconstriction mediated by re-
duced rate of noradrenaline metabolism. It could be hy-
pothesized that enhanced adrenergic tone might induce
peripheral vasoconstriction leading to ischemic muscles
damage, associated with myalgia, and augmented levels of
unspecific tissue necrosis enzymes (CPK and LDH).
In the Case 1 patient, chronic leg edema, probably due
to CVI, could have caused higher baseline intravascular
and intracapillary pressures, making tissues more vulner-
able to trauma from vasoconstriction. In the Case 2 pa-
tient, an acute hemorrhoidal attack could have been
severe enough to cause tissue ischemia and subsequent
LDH elevation without hemolysis; prolonged diosmin
therapy could have enhanced tissue necrosis due to its
vasotonic effects, acting as a concurrent cause of LDH
increase. It seems that the association between diosmin
and the reported AEs should be ascribed to an individual
and subjective predisposition to the adrenergic effects of
diosmin, and/or to the presence of comorbidities.
Conclusions
To the best of our knowledge, these are first cases of
increased serum CPK and LDH levels during diosmin
therapy to date reported.We ascribe these reported ADRs to a concurrence of
events: an individual predisposition to the vasotonic ef-
fects of diosmin, and the presence of severe comorbidi-
ties that may have enhanced noradrenaline tone in some
predisposed patients.
Drugs containing diosmin are frequently prescribed by
general practitioners. Diosmin is usually considered safe
because of its natural origin, and its phytochemical and
pharmacological features. Physicians and patients must
be aware of these rare, but possible ADRs.
Further studies are needed to investigate in more de-
tail the underlying causes of these ADRs.
Consent
Written informed consent was obtained from both pa-
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of the written consent is available for review by the
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